Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland Sells 2,353 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland sold 2,353 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $96.60, for a total value of $227,299.80. Following the transaction, the chief executive officer now owns 150,824 shares in the company, valued at $14,569,598.40. The trade was a 1.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Blueprint Medicines Trading Down 1.5 %

Shares of Blueprint Medicines stock opened at $95.08 on Friday. Blueprint Medicines Co. has a 1 year low of $70.89 and a 1 year high of $121.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The stock has a market cap of $6.04 billion, a PE ratio of -45.06 and a beta of 0.59. The firm has a fifty day moving average price of $91.43 and a 200 day moving average price of $97.91.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The business had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company’s revenue for the quarter was up 126.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($2.20) EPS. Equities research analysts predict that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Hedge Funds Weigh In On Blueprint Medicines

Several large investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in Blueprint Medicines by 22.5% in the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after buying an additional 729,055 shares in the last quarter. State Street Corp grew its holdings in Blueprint Medicines by 16.2% in the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock valued at $255,827,000 after purchasing an additional 385,818 shares during the period. Geode Capital Management LLC increased its position in shares of Blueprint Medicines by 1.4% in the third quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company’s stock valued at $136,942,000 after buying an additional 20,703 shares in the last quarter. American Century Companies Inc. raised its stake in shares of Blueprint Medicines by 4.2% during the 2nd quarter. American Century Companies Inc. now owns 802,733 shares of the biotechnology company’s stock worth $86,519,000 after buying an additional 32,600 shares during the period. Finally, Millennium Management LLC lifted its position in shares of Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock valued at $67,646,000 after buying an additional 529,566 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. UBS Group started coverage on Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target on the stock. StockNews.com raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Friday, November 15th. Finally, JPMorgan Chase & Co. began coverage on Blueprint Medicines in a report on Thursday, November 14th. They set an “overweight” rating and a $126.00 target price for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.11.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.